Mylan exec blasts financier&#39;s plan to block King merger
603432
PITTSBURGH The chief executive of Mylan Laboratories says a move by Wall Street financier Carl Icahn (EYE&#39;-kahn) to halt Mylan&#39;s acquisition of King Pharmaceuticals is wrongheaded.
768370
Billionaire investor Carl Icahn yesterday offered to purchase Mylan Laboratories for $20 per share, part of his plan to derail the Canonsburg generic drug maker&#39;s proposed acquisition of King Pharmaceuticals.
588024
Financier Carl Icahn on Friday offered to buy the shares of generic drugmaker Mylan Laboratories  that he does not already own for &#36;4.9 billion, or &#36;20 a share, according to a government filing.
406523
UBS Global Asset Management told Mylan Laboratories Inc. that Mylan&#39;s proposed acquisition of King Pharmaceuticals Inc. is dilutive to Mylan shareholders and not in the best interests of the investment firm&#39;s
659975
Mylan Laboratories Inc. on Wednesday  said it was unlikely to complete its $3.37 billion acquisition  of King Pharmaceuticals Inc. under the current transaction  terms, or on time, because of King's need to restate some past  financial results.
543076
Financier Carl Icahn said Monday King Pharmaceutical Inc.&#39;s possible need to restate earnings reinforces his belief that an acquisition of King by Mylan Laboratories Inc.
522707
The American billionaire used his 28.1 per cent stake to block the re-election of three directors at an AGM three days ago. It is seen as an act of revenge after the board called off takeover talks last month.
704704
Troubled King Pharmaceuticals' latest accounting woes threaten to scuttle its merger with Mylan.
443622
Business & money: Â· Outdoor leisure group chairman attacks 'bullying' Â· Sports Direct chief wants his own management
260004
Mylan Laboratories Inc. on Wednesday said it was unlikely to complete its &#36;3.80 billion acquisition of King Pharmaceuticals Inc. at the current price because of King's need to restate earnings.
693432
Business & money: Owner outlines his strategy to revive label in face of growing opposition to plans to cut up to 2,000 jobs
226932
Billionaire financier Carl Icahn offered to buy Mylan Laboratories Inc., the largest US maker of generic medicines, for about $5.38 billion to block Mylan&#39;s proposed purchase of King Pharmaceuticals Inc.
608996
Generic drug maker Mylan Laboratories Inc.  said on Friday it is raising at least about $993.6 million in a public offering of notes and common shares, with proceeds intended for global operations and potential acquisitions.
398654
A Dow Jones  board member who is  also part of the family that controls the company has launched  a last-ditch effort to block a takeover by Rupert Murdoch&#39;s  News Corp. (NWSa.N), the Wall Street Journal reported on  Sunday.
247690
Carl Icahn has launched another of his multibillion-dollar shock-and-awe raids for a company - this time on the nation&#39;s biggest generic drug maker, Mylan.
580086
WASHINGTON (CBS.MW) -- Mylan Laboratories (MYL) , responding to the latest in a series of letters from investor Carl Icahn, reasserted its position that acquiring King Pharmaceuticals (KG) is in the long-term interest of the generic drugmaker and its
755767
Mylan Laboratories Inc.'s MYL.N board  on Monday rebuffed financier Carl Icahn's bid to buy the  company, and said it remains committed to its $3.37 billion  purchase of brand-name drug-maker King Pharmaceuticals Inc.  KG.N.